Randomized Controlled Study to Evaluate the Clinical Outcomes of Rheumatoid Arthritis Treated with Method of Activating Blood Circulation by Removing Blood Stasis

INTERVENTION: Group A:observation group: Leflunomide Tablets, from the first day to the third day, 50mg, qd, po, then 20mg, qd, po. Ligustrazine Powder‐Needle, 0.12g, solubling in 5% GS/NS 100ml, qd, iv, in 30 to 60 minutes. ;Group B:control group: Leflunomide Tablets, from the first day to the third day, 50mg, qd, po, then 20mg, qd, po. ; CONDITION: M06.991 Rheumatoid Arthritis PRIMARY OUTCOME: Rest pain, pressing pain on joints, arthrocele, early morning stiffness, average grip of both hands; SECONDARY OUTCOME: Laboratory examinations: ESR, RF, CRP, IgA, IgG, IgM, hemorheology, X‐ray, Pattern information of Chinese Medicine; INCLUSION CRITERIA: 1. Be diagnosed with RA as defined by the 1987 America College of Rheumatology (ACR) criteria, and the disease progression is in the I, II, or III phase, in active phase; 2. Sign the informed consent by patient or guardian; 3. Platelet count>=100*10^9/L.